Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vyriad, Inc.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Omnis Pharmaceuticals, Inc.
- Magnis Therapeutics, LLC.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.